Summary
Pfizer Inc. (PFE) announced through its wholly-owned Dutch subsidiary, Pfizer Netherlands International Finance B.V., the successful completion of a substantial public offering of senior unsecured notes. The offering, totaling €3.25 billion across four tranches with varying maturities and interest rates, was made under a previously established shelf registration statement. This debt issuance represents a strategic move by Pfizer to raise capital, likely for general corporate purposes, potential acquisitions, or to refinance existing debt. The fully and unconditionally guaranteed nature of the notes by Pfizer Inc. provides investors with direct recourse to the parent company, enhancing the security of their investment. Investors should note the specific coupon rates and maturity dates for each tranche of notes, which indicate the cost of borrowing for Pfizer over different time horizons.
Key Highlights
- 1Pfizer Inc. subsidiary completed a public offering of €3.25 billion in senior unsecured notes.
- 2The offering comprises four tranches: €750M of 2.875% Notes due 2029, €1B of 3.250% Notes due 2032, €750M of 3.875% Notes due 2037, and €800M of 4.250% Notes due 2045.
- 3The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc.
- 4The offering was conducted under Pfizer's existing shelf registration statement on Form S-3, as amended.
- 5The issuance involves a Base Indenture and a First Supplemental Indenture, with The Bank of New York Mellon acting as trustee.
- 6Underwriting and pricing agreements were executed with several underwriters on May 14, 2025.
- 7Legal opinions regarding the validity of the notes and guarantee have been filed.